Subscribe On

Apple Podcasts Spotify Youtube Music iHeartRadio Amazon Music

10.02.24

Water-Free Ciclosporin-Based Eye Drop for DED Approved in Europe

Novaliq’s water-free ciclosporin-based eye drop for dry eye disease is approved in Europe; the FDA approves first new ophthalmic steroid in over 15 years; and the first slit-lamp mounted rebound tonometer is launched in the US and Europe.

View full description +

Apple Podcasts

Spotify

Youtube Music

iheartradio

Amazon Music

View more +

MORE EPISODES

01.28.26

FDA Approves Label Supplement for iDose TR

01.21.26

Rayner Launches New Phaco System

01.14.26

Moorfields Researchers Reveal Promising Treatment for Hypotony

01.07.26

Staar Terminates Merger with Alcon

12.31.25

2025 Year in Review - Part 2

12.24.25

2025 Year in Review - Part 1

12.17.25

Update on Reproxalap PDUFA Timing

12.10.25

New Glaucoma Technologies Advance in Clinical Development

12.03.25

Eylea HD Approved for RVO and Extended Dosing

11.26.25

Leaders Discuss Emerging Technologies in Glaucoma

11.18.25

Live Coverage of B+L Investor Day

11.12.25

Ryjunea Approved in the UK for Myopia

11.05.25

Ophthalmic Executives Provide Company Updates (Part 2 of 2)

10.29.25

Ophthalmic Executives Provide Company Updates (Part 1 of 2)

10.22.25

Breaking News from the AAO Meeting in Orlando

10.15.25

First Robotic Cataract Surgery Performed

10.08.25

Lenz Therapeutics' Vizz Commerically Launched

10.01.25

Visionary Breakthroughs: A Spotlight on Innovations in Eye Care (Part 2 of 2)

09.24.25

Visionary Breakthroughs: A Spotlight on Innovations in Eye Care (Part 1 of 2)

09.17.25

Breaking News From the ESCRS Congress in Copenhagen

09.10.25

Vision Advocacy Leaders Speak Out Against Proposed NEI Cuts

09.03.25

Update on Investigational Treatments for Retinal Diseases

08.27.25

CE Certification for New Glaucoma Surgical Implant

08.20.25

Special Report: TFOS DEWS III Leaders Discuss New DED Guidance

08.13.25

First Commerical Surgeries Performed with MacTel Therapy

08.06.25

Alcon Acquires Staar for $1.5 Billion

07.30.25

Tryptyr Now Available in US

07.23.25

Harrow Adds Biosimilars to US Portfolio

07.16.25

AECOS Presentation Summaries

07.09.25

Alcon Acquires LumiThera

07.02.25

Glaukos' MIGS Technology Certified in Europe; New Phase 3 Data for Presbyopia Drop

06.25.25

Special Report: Update on Holland Foundation

06.18.25

TFOS DEWS III Published

06.11.25

First Myopia Drug Approved in Europe

06.04.25

Alcon Gains FDA Approval for Novel DED Drug

05.28.25

Special Report: Executives Discuss Overcoming Challenges

05.21.25

B+L Launches New Scleral Lenses Technology

05.14.25

B+L Receives Approval in Europe for LuxLife IOL

05.07.25

Ophthalmic Leaders Launch SightLine Meeting

04.30.25

Breaking News from the ASCRS Meeting in Los Angeles

04.23.25

FDA Issues CRL to Regeneron for Eylea HD Extended Dosing

04.16.25

Orasis Launches Presbyopia Eye Drop Qlosi

04.09.25

Utilizing AI to Provide DR Screening to Underserved Communities

04.02.25

Alcon Launches PanOptix Pro in US

03.26.25

Alcon Announces Plans to Acquire Lensar

03.19.25

FDA Expands Product Label for Iluvien

03.12.25

FDA Approves First Treatment for MacTel

03.05.25

Haag-Streit Launches METIS 900 Microscope

02.26.25

New Myopia Software on Pentacam AXL

02.19.25

Alcon Voyager DSLT Fully Launched in US

02.12.25

AAO Opposes NIH Research Funding Proposal

02.05.25

FDA Approves Genentech's Susvimo Ocular Implant for DME

01.29.25

Norlase Launches First Pattern Scanning LIO

01.22.25

Zeiss MEL 90 Approved by FDA

01.15.25

Special Report – Increasing Access to Care Through the Cure Blindness Project

01.08.25

Glaukos Submits NDA for Epi-On CLX Candidate

01.01.25

2024 Year in Review — Part 2

12.25.24

2024 Year in Review — Part 1

12.18.24

B+L Bolsters Glaucoma Offerings with Elios Acquisition

12.11.24

Phase 3 Results for Novel Sedation Tablet

12.04.24

Phakic IOL for Presbyopia Approved in Europe

11.27.24

Special Report: OWL Celebrates 20th Anniversary

11.20.24

Lumithera CEO Discusses FDA Authorization for Veleda for Dry AMD

11.13.24

Ophthalmic Executives Provide Company Updates (Part 2 of 2)

11.06.24

Ophthalmic Executives Provide Company Updates (Part 1 of 2)

10.30.24

Posterior Segment Company Updates

10.23.24

Breaking News From the AAO Meeting in Chicago

10.16.24

B+L Receives FDA Approval for enVista Envy IOL

10.09.24

Aldeyra Resubmits NDA for DED Drug Reproxalap

10.02.24

Water-Free Ciclosporin-Based Eye Drop for DED Approved in Europe

09.25.24

Two Partnerships Formed to Advance Glaucoma Treatments

09.18.24

Breaking News From the ESCRS Congress in Barcelona (Part 2 of 2)

09.11.24

Weekly Headlines: Zeiss Lenticule Extraction for Hyperopia

09.04.24

Weekly Headlines: First Therapy for Acanthamoeba Keratitis Approved in Europe

08.28.24

Weekly Headlines: Rayner Unveils First AI-Designed Spiral IOL

08.21.24

Weekly Headlines: Gene Therapies for IRDs Receive FDA Rare Pediatric Disease Designations

08.14.24

Weekly Headlines: Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap

08.07.24

Weekly Headlines: Two Phase 3 Trials for Dry and Wet AMD Drug Candidates Begin